BRPI0511196A - polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição - Google Patents

polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição

Info

Publication number
BRPI0511196A
BRPI0511196A BRPI0511196-0A BRPI0511196A BRPI0511196A BR PI0511196 A BRPI0511196 A BR PI0511196A BR PI0511196 A BRPI0511196 A BR PI0511196A BR PI0511196 A BRPI0511196 A BR PI0511196A
Authority
BR
Brazil
Prior art keywords
conjugate
polypeptide
virus
composition
hiv
Prior art date
Application number
BRPI0511196-0A
Other languages
English (en)
Inventor
Phillip A Patten
Sridhar Viswanathan
Torben Lauesgaard Nissen
Anne Vogt
Harald Kropshofer
Ralf Schumacher
Stephan Fischer
Stefan Seeber
Adelbert Grossmann
Friederike Hesse
Andreas Schaubmar
Roberto Falkenstein
Hans Koll
Markus Dembowski
Original Assignee
Maxygen Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc, Hoffmann La Roche filed Critical Maxygen Inc
Publication of BRPI0511196A publication Critical patent/BRPI0511196A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

POLIPEPTìDEO ISOLADO OU RECOMBINANTE, CONJUGADO, COMPOSIçãO, CéLULA HOSPEDEIRA, VETOR, MéTODOS PARA PREPARAR UM POLIPEPTìDEO, PARA PREPARAR UM CONJUGADO, PARA REDUZIR O NúMERO DE CóPIAS DE UM VìRUS EM CéLULAS INFECTADAS COM O VìRUS, PARA REDUZIR O NìVEL DE RNA HCV, DNA HBV E RNA HIV NO SORO DE UM PACIENTE INFECTADO COM HCV, HBV E HIV, E, USO DO POLIPEPTìDEO, DO CONJUGADO OU DA COMPOSIçãO. A presente invenção fornece polipeptídeos e conjugados de interferon-alfa e ácidos nucleicos que codificam os polipeptídeos. A invenção também inclui composições que compreendem esses polipeptídeos, conjugados e ácidos nucleicos; células contendo ou expressando os polipeptídeos, conjugados e ácidos nucleicos; métodos de fabricação dos polipeptídeos, conjugados e ácidos nucleicos; e métodos de uso dos polipeptídeos, conjugados e ácidos nucleicos.
BRPI0511196-0A 2004-05-19 2005-05-18 polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição BRPI0511196A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57250404P 2004-05-19 2004-05-19
PCT/US2005/017471 WO2005113592A2 (en) 2004-05-19 2005-05-18 Interferon-alpha polypeptides and conjugates

Publications (1)

Publication Number Publication Date
BRPI0511196A true BRPI0511196A (pt) 2007-12-04

Family

ID=35428915

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511196-0A BRPI0511196A (pt) 2004-05-19 2005-05-18 polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição

Country Status (14)

Country Link
US (9) US7318918B2 (pt)
EP (1) EP1753779A2 (pt)
JP (1) JP2008507298A (pt)
CN (1) CN101115769A (pt)
AR (1) AR049177A1 (pt)
AU (1) AU2005245918A1 (pt)
BR (1) BRPI0511196A (pt)
CA (1) CA2566247A1 (pt)
IL (1) IL178470A0 (pt)
MX (1) MXPA06013412A (pt)
NO (1) NO20065084L (pt)
RU (1) RU2006145020A (pt)
TW (1) TW200611910A (pt)
WO (1) WO2005113592A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537762A (ja) 1999-01-05 2002-11-12 トラスティーズ オブ ボストン ユニバーシティ 改良型核酸クローニング
US20040005673A1 (en) 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
WO2002008408A2 (en) * 2000-07-21 2002-01-31 Trustees Of Boston University Modular vector systems
US7435562B2 (en) * 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
EP1759521B1 (en) * 2004-05-12 2016-06-29 Synchronoss Technologies, Inc. Advanced contact identification system
US7485423B2 (en) 2004-11-11 2009-02-03 Modular Genetics, Inc. Ladder assembly and system for generating diversity
US20080124302A1 (en) * 2005-03-09 2008-05-29 Guangwen Wei Uses of Recombinant Super-Compound Interferons
MX2007014524A (es) 2005-05-18 2008-02-07 Maxygen Inc Polipeptidos desarrollados de interferon-alfa.
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
US20080014616A1 (en) * 2006-07-11 2008-01-17 Kevin Jarrell Methods of introducing targeted diversity into nucleic acid molecules
WO2008013082A1 (en) * 2006-07-25 2008-01-31 Galpharma Co., Ltd. Galectin 9-polymer conjugate
US7808342B2 (en) * 2006-10-02 2010-10-05 Skyworks Solutions, Inc. Harmonic phase tuning filter for RF switches
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009006579A1 (en) * 2007-07-05 2009-01-08 Pharmaessentia Corp. Peptide-polymer conjugates
EP2195338B1 (en) * 2007-10-01 2013-12-25 Pharmaessentia Corp. N-terminal modified interferon-alpha
AU2009204998B2 (en) 2008-01-18 2014-03-27 F. Hoffmann-La Roche Ag Purification of non-glycosylated proteins
US7954022B2 (en) * 2008-01-30 2011-05-31 Alcatel-Lucent Usa Inc. Apparatus and method for controlling dynamic modification of a scan path
TW201032826A (en) * 2008-11-17 2010-09-16 Genentech Inc Method and formulation for reducing aggregation of a macromolecule under physiological conditions
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
US9944688B2 (en) 2011-06-02 2018-04-17 Hanmi Science Co., Ltd. Non-peptidyl polymer-insulin multimer and method for producing the same
US10081684B2 (en) 2011-06-28 2018-09-25 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
CN102358897B (zh) * 2011-10-31 2013-02-13 北京三元基因工程有限公司 重组人寡腺苷酸合成酶-1的制备方法
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
ES2630106T3 (es) * 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
EP3397287B8 (en) 2015-12-30 2025-07-23 F. Hoffmann-La Roche AG Formulations with reduced degradation of polysorbate
CN116769054A (zh) * 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
RU2650755C1 (ru) * 2017-05-24 2018-04-17 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С
JP2023511946A (ja) * 2020-01-24 2023-03-23 アルカームス ファーマ アイルランド リミテッド 精製方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
ES506955A0 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
IT1167610B (it) 1982-01-19 1987-05-13 Cetus Corp Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPS60152058A (ja) * 1984-01-20 1985-08-10 Toshiba Corp 半導体記憶装置
DE3685996T2 (de) * 1985-06-11 1993-01-14 Ciba Geigy Ag Hybrid-interferone.
US4695626A (en) * 1986-07-29 1987-09-22 Pfizer Inc. 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
WO1992006707A1 (en) 1990-10-17 1992-04-30 Amgen Inc. Methods and compositions for the treatment of cell proliferation disorders
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
JP4001379B2 (ja) 1994-03-07 2007-10-31 インペリアル カレッジ オブ サイエンス，テクノロジー アンド メディシン ウィルス感染を治療する薬剤の調製におけるインターフェロンのサブタイプの使用
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
JP2002534119A (ja) 1999-01-14 2002-10-15 ボルダー バイオテクノロジー， インコーポレイテッド 自由システイン残基を有するタンパク質の生産方法
AU3725600A (en) * 1999-03-02 2000-09-21 Maxygen, Inc. Surrogate orphan ligands for orphan receptors
KR20020018197A (ko) 1999-05-19 2002-03-07 추후보정 Ｆｃ 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
CA2385045A1 (en) * 1999-10-07 2001-04-12 Maxygen, Inc. Ifn-alpha homologues
SK8292002A3 (en) * 1999-11-12 2002-12-03 Maxygen Holdings Ltd A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2002044197A2 (en) 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
KR100459105B1 (ko) 2001-02-15 2004-12-03 선바이오(주) 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체
AU2003293668A1 (en) 2002-11-15 2004-06-15 F. Hoffmann-La Roche Ag Positional isomers of peg ifn alpha 2a
US20040219131A1 (en) * 2002-11-18 2004-11-04 Maxygen, Inc. Interferon-alpha polypeptides and conjugates

Also Published As

Publication number Publication date
AR049177A1 (es) 2006-07-05
US20050266465A1 (en) 2005-12-01
US7541436B2 (en) 2009-06-02
JP2008507298A (ja) 2008-03-13
TW200611910A (en) 2006-04-16
US7541163B2 (en) 2009-06-02
US20070225204A1 (en) 2007-09-27
US7318918B2 (en) 2008-01-15
US7537755B2 (en) 2009-05-26
WO2005113592A3 (en) 2006-04-06
US20080076710A1 (en) 2008-03-27
WO2005113592A2 (en) 2005-12-01
EP1753779A2 (en) 2007-02-21
US20070020235A1 (en) 2007-01-25
US20080031853A1 (en) 2008-02-07
NO20065084L (no) 2006-12-01
US20070020734A1 (en) 2007-01-25
CA2566247A1 (en) 2005-12-01
US7531630B2 (en) 2009-05-12
MXPA06013412A (es) 2007-01-23
US20070025966A1 (en) 2007-02-01
US20080171363A1 (en) 2008-07-17
CN101115769A (zh) 2008-01-30
AU2005245918A1 (en) 2005-12-01
US20070225205A1 (en) 2007-09-27
RU2006145020A (ru) 2008-06-27
IL178470A0 (en) 2007-02-11
US7531324B2 (en) 2009-05-12

Similar Documents

Publication Publication Date Title
Chaturvedi et al. Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma
Zhang et al. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant
Andrés et al. African swine fever virus polyproteins pp220 and pp62 assemble into the core shell
Vivekanandan et al. Hepatitis B virus replication induces methylation of both host and viral DNA
Neuman et al. Antisense morpholino-oligomers directed against the 5′ end of the genome inhibit coronavirus proliferation and growth
Kolupaeva et al. An enzymatic footprinting analysis of the interaction of 40S ribosomal subunits with the internal ribosomal entry site of hepatitis C virus
Cheng et al. Specific interaction between the hepatitis C virus NS5B RNA polymerase and the 3′ end of the viral RNA
Tavis et al. The duck hepatitis B virus polymerase is activated by its RNA packaging signal, ɛ
Huang et al. Alphacoronavirus transmissible gastroenteritis virus nsp1 protein suppresses protein translation in mammalian cells and in cell-free HeLa cell extracts but not in rabbit reticulocyte lysate
Fan et al. Specific in vitro association between the hepatitis C viral genome and core protein
Vázquez et al. Mutation analysis of the GDD sequence motif of a calicivirus RNA-dependent RNA polymerase
BR122019013216B8 (pt) ensaio imunológico para análise de uma vacina contra influenza
WO2009039248A8 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
BR0016145A (pt) Clones infecciosos
WO2008103380A3 (en) Hepatitis b virus compositions and methods of use
Walter et al. The polypeptides of adenovirus: IV. Detection of early and late virus-induced polypeptides and their distribution in subcellular fractions
Xia et al. PASylated interferon α efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice
Glass et al. Identification of a trans-acting activity from liver that stimulates hepatitis A virus translation in vitro
Jarczak et al. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons
Lang et al. Immunotherapy for HCV infection: next steps
Macejak et al. Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA
Lu et al. Woodchuck gamma interferon upregulates major histocompatibility complex class I transcription but is unable to deplete woodchuck hepatitis virus replication intermediates and RNAs in persistently infected woodchuck primary hepatocytes
Mirazimi et al. ATP is required for correct folding and disulfide bond formation of rotavirus VP7
BRPI0209416A2 (pt) Novos vetores de expressão e uso dos mesmos
Pudi et al. A peptide derived from RNA recognition motif 2 of human la protein binds to hepatitis C virus internal ribosome entry site, prevents ribosomal assembly, and inhibits internal initiation of translation

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]